Update on rituximab: An established treatment for all immune-mediated kidney diseases?

Nephron - Clinical Practice

Volumn 126, Issue 3, 2014, Pages 97-109

  Evans, Rhys ^a   Salama, Alan D ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Antineutrophil cytoplasm antibody; Idiopathic membranous nephropathy; Immune mediated kidney disease; Lupus nephritis; Rituximab; Systemic lupus erythematosus

Indexed keywords

CREATININE; METHYLPREDNISOLONE; PLACEBO; PREDNISOLONE; RITUXIMAB; CD20 ANTIGEN; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ANCA ASSOCIATED VASCULITIS; CREATININE BLOOD LEVEL; CRYOGLOBULINEMIA; DRUG SAFETY; DRUG TOLERABILITY; GLOMERULONEPHRITIS; GLOMERULOPATHY; GLOMERULOSCLEROSIS; HEPATITIS C; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNE MEDIATED RENAL DISEASE; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DISEASE; LUPUS ERYTHEMATOSUS NEPHRITIS; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC VASCULITIS; URINE SEDIMENT; AGAMMAGLOBULINEMIA; B LYMPHOCYTE; CHEMICALLY INDUCED; DRUG ADMINISTRATION; IMMUNOLOGY; INFECTION; KIDNEY DISEASES; ANTIGEN ANTIBODY COMPLEX; ANTIVIRAL THERAPY; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; CRYOGLOBULINEMIC VASCULITIS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG USE; IDIOPATHIC DISEASE; INFECTIOUS COMPLICATION; MAINTENANCE THERAPY; MEMBRANOUS GLOMERULONEPHRITIS; PHASE 1 CLINICAL TRIAL (TOPIC);

AGAMMAGLOBULINEMIA; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; B-LYMPHOCYTES; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOLOGIC FACTORS; INFECTION; KIDNEY DISEASES;

EID: 84897117245     PISSN: None     EISSN: 16602110     Source Type: Journal    
DOI: 10.1159/000358887     Document Type: Review

References (61)

1. Ramanath V, Nistala R, Chaudhary K: Update on the role of rituximab in kidney diseases and transplant. Expert Opin Biol Ther 2012; 12:223-233.
2. Salama AD, Pusey CD: Drug insight: ritux-imab in renal disease and transplantation. Nat Clin Pract Nephrol 2006; 2:221-230. (Pubitemid 43787288)
3. Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, Rosenblatt J, et al: The relationship of FcγRIIIa genotype to degree of B-cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003; 48:455-459. (Pubitemid 36278014)
4. Kimby E: Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005; 31:456-473.
5. Mohrbacher A: B-cell non-Hodgkin's lym-phoma: rituximab safety experience. Arthritis Res Ther 2005; 7(suppl 3):S19-S25. (Pubitemid 40936613)
6. Albert D, Dunham J, Khan S, Stansberry J, Kolasinski S, Tsai D, et al: Variability in the biological response to anti-CD20 B-cell depletion in systemic lupus erythematosus. Ann Rheum Dis2008; 67:1724-1731.
7. Thurlings RM, Teng O, Vos K, Gerlag DM, Aarden L, Stapel SO, et al: Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2010; 69:409-412.
8. Carson KR, Evens AM, Richey EA, Haber-mann TM, Focosi D, Seymour JF, et al: Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113:4834-4840.
9. Smith RM, Jones RB, Guerry MJ, Laurino S, Catapano F, Chaudhry A, et al: rituximab for remission maintenance in relapsing an-tineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012; 64: 3760-3769.
10. Rhee EP, Laliberte KA, Niles JL: Rituximab as maintenance therapy for anti-neutrophil cy-toplasmic antibody-associated vasculitis. Clin J Am Soc Nephrol 2010; 5:1394-1400.
11. Specks U, Merkel PA, Seo P, Spiera R, Lang-ford CA, Hoffman GS, et al: Efficacy of remission-induction regimens for ANCA-associ-ated vasculitis. N Engl J Med 2013; 369:417-427.
12. Besada E, Koldingsnes W, Nossent JC: Long-term efficacy and safety of preemptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre. Rheumatology 2013; 52:2041-2047.
13. Lightstone L: The landscape after LUNAR: rituximab's crater-filled path. Arthritis Rheum 2012; 64:962-965.
14. Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J, Rohde RD: Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 2000; 35:904-914. (Pubitemid 30238204)
15. Houssiau FA, Vasconcelos C, D'Cruz D, Se-bastiani GD, Garrido Ed Ede R, Danieli MG, et al: Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46:2121-2131.
16. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al: Mycopheno-late mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009; 20:1103-1112.
17. Houssiau FA, D'Cruz D, Sangle S, Remy P, Vasconcelos C, Petrovic R, et al: Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis 2010; 69:2083-2089.
18. Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, et al: Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011; 365: 1886-1895.
19. Mosca M, Tani C, Carli L, Bombardieri S: Glucocorticoids in systemic lupus erythema-tosus. Clin Exp Rheumatol 2011; 29(suppl 68):S126-S129.
20. Diaz-Lagares C, Croca S, Sangle S, Vital EM, Catapano F, Martinez-Berriotxoa A, et al: Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev 2012; 11: 357-364.
21. Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA: Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus 2009; 18:767-776.
22. Jonsdottir T, Zickert A, Sundelin B, Henriks-son EW, van Vollenhoven RF, Gunnarsson I: Long-term follow-up in lupus nephritis patients treated with rituximab-clinical and his-topathological response. Rheumatology 2013; 52:847-855.
23. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al: Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62: 222-233.
24. Rovin BH, Furie R, Latinis K, Looney RJ, Fer-venza FC, Sanchez-Guerrero J, et al: Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum 2012; 64:1215-1226.
25. Condon MB, Ashby D, Pepper RJ, Cook HT, Levy JB, Griffith M, et al: Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 2013; 72: 1280-1286.
26. De Groot K, Harper L, Jayne DR, Flores Su-arez LF, Gregorini G, Gross WL, et al: Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cyto-plasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009; 150: 670-680.
27. Harper L, Morgan MD, Walsh M, Hoglund P, Westman K, Flossmann O, et al: Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Ann Rheum Dis 2012; 71:955-960.
28. Little MA, Nightingale P, Verburgh CA, Hauser T, De Groot K, Savage C, et al: Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculi-tis. Ann Rheum Dis 2010; 69:1036-1043.
29. Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, et al: Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363:211-220.
30. Stone JH, Merkel PA, Spiera R, Seo P, Lang-ford CA, Hoffman GS, et al: Rituximab versus cyclophosphamide for ANCA-associated vas-culitis. N Engl J Med 2010; 363:221-232.
31. Terrier B, Pagnoux C, Karras A, Khouatra C, Aumaitre O, Cohen P, et al: Rituximab versus azathioprine for maintenance in antineutro-phil cytoplasmic antibodies (ANCA)-associ-ated vasculitis (MAINRITSAN): follow-up at 34 months. Presse Med 2013; 42:778-779.
32. http://clinicaltrials.gov/show/NCT01731561.
33. http://clinicaltrials.gov/ct2/show/NCT01697267.
34. Annear NM, Cook HT, Atkins M, Pusey CD, Salama AD: Non-hepatitis virus associated mixed essential cryoglobulinemia. Kidney Int 2010; 77:161-164.
35. Damoiseaux J, Cohen Tervaert JW: Diagnostics and treatment of cryoglobulinaemia: it takes two to tango. Clin Rev Allergy Immunol 2013, Epub ahead of print.
36. Dammacco F, Sansonno D: Therapy for hepatitis C virus-related cryoglobulinemic vascu-litis. N Engl J Med 2013; 369:1035-1045.
37. Saadoun D, Resche Rigon M, Sene D, Terrier B, Karras A, Perard L, et al: Rituximab plus Peg-interferon-α/ribavirin compared with Peg-interferon-α/ribavirin in hepatitis C-re-lated mixed cryoglobulinemia. Blood 2010; 116:326-334.
38. Dammacco F, Tucci FA, Lauletta G, Gatti P, De Re V, Conteduca V, et al: Pegylated interferon-α, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood 2010; 116:343-353.
39. De Vita S, Quartuccio L, Isola M, Mazzaro C, Scaini P, Lenzi M, et al: A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 2012; 64:843-853.
40. Sneller MC, Hu Z, Langford CA: A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum 2012; 64:835-842.
41. Terrier B, Carrat F, Krastinova E, Marie I, Launay D, Lacraz A, et al: Prognostic factors of survival in patients with non-infectious mixed cryoglobulinaemia vasculitis: data from 242 cases included in the CryoVas survey. Ann Rheum Dis 2013; 72:374-380.
42. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glo-merulonephritis. Kidney Int Suppl 2012; 2: 139-274.
43. Ponticelli C, Glassock RJ: Glomerular diseases: membranous nephropathy-a modern view. Clin J Am Soc Nephrol 2013, Epub ahead of print.
44. Howman A, Chapman TL, Langdon MM, Ferguson C, Adu D, Feehally J, et al: Immu-nosuppression for progressive membranous nephropathy: a UK randomised controlled trial. Lancet 2013; 381:744-751.
45. Ruggenenti P, Cravedi P, Chianca A, Perna A, Ruggiero B, Gaspari F, et al: rituximab in id-iopathic membranous nephropathy. J Am Soc Nephrol 2012; 23:1416-1425.
46. Fervenza FC, Abraham RS, Erickson SB, Ira-zabal MV, Eirin A, Specks U, et al: Rituximab therapy in idiopathic membranous nephrop-athy: a 2-year study. Clin J Am Soc Nephrol 2010; 5:2188-2198.
47. http://clinicaltrials.gov/show/NCT01508468.
48. http://clinicaltrials.gov/show/NCT01180036.
49. http://clinicaltrials.gov/show/NCT01955187.
50. Haffner D, Fischer DC: Nephrotic syndrome and rituximab: facts and perspectives. Pediatr Nephrol 2009; 24:1433-1438.
51. Gulati A, Sinha A, Jordan SC, Hari P, Dinda AK, Sharma S, et al: Efficacy and safety of treatment with rituximab for difficult steroid-resistant and-dependent nephrotic syndrome: multicentric report. Clin J Am Soc Nephrol 2010; 5:2207-2212.
52. Francois H, Daugas E, Bensman A, Ronco P: Unexpected efficacy of rituximab in multi-relapsing minimal change nephrotic syndrome in the adult: first case report and pathophysiological considerations. Am J Kidney Dis 2007; 49:158-161. (Pubitemid 44932200)
53. Munyentwali H, Bouachi K, Audard V, Remy P, Lang P, Mojaat R, et al: Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. Kidney Int 2013; 83:511-516.
54. Bruchfeld A, Benedek S, Hilderman M, Me-din C, Snaedal-Jonsdottir S, Korkeila M: Rituximab for minimal change disease in adults: long-term follow-up. Nephrol Dial Transplant 2013, Epub ahead of print.
55. Takei T, Itabashi M, Moriyama T, Kojima C, Shiohira S, Shimizu A, et al: Effect of single-dose rituximab on steroid-dependent minimal-change nephrotic syndrome in adults. Nephrol Dial Transplant 2013; 28:1225-1232.
56. http://clinicaltrials.gov/show/NCT01268033.
57. Sugiura H, Takei T, Itabashi M, Tsukada M, Moriyama T, Kojima C, et al: Effect of single-dose rituximab on primary glomerular diseases. Nephron Clin Pract 2011; 117:c98-c105.
58. Javaugue V, Karras A, Glowacki F, McGregor B, Lacombe C, Goujon JM, et al: Long-term kidney disease outcomes in fibrillary glomer-ulonephritis: a case series of 27 patients. Am J Kidney Dis 2013; 62:679-690.
59. Syeda UA, Singer NG, Magrey M: Anti-glo-merular basement membrane antibody disease treated with rituximab: a case-based review. Se-min Arthritis Rheum 2013; 42: 567-572.
60. Cuadrado MJ, Sciascia S, Bosch X, Khamash-ta MA, Ramos-Casals M: Is it time for bio-similars in autoimmune diseases? Autoim-mun Rev 2013; 12:954-957.
61. Turner-Stokes T, Sandhu E, Pepper RJ, Sto-laqiewicz NE, Ashley C, Dinneen D, et al: Induction treatment of ANCA-associated vas-culitis with a single dose of rituximab. Rheumatology (Oxford) 2014, Epub ahead of print.